NTI
NEUROTECH FPO [NTI]
Healthcare · ASX Small Cap
$0.0130 -7.1%
Updated 26 Mar 2026 · Scores refresh every scan
Score Breakdown
Technical66
Catalyst64
Sentiment50
Fundamental70
Momentum48
Risk Gate31
Get alerts when NTI's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- MACD momentum is picking up steam
- Above-average volume (1.6x) on a red day — sellers in control
- On a tear — up 30.0% over the last 5 days
- Beating the Small Ords index — relative strength of 1.12, so it's outpacing the pack
- Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
- Volatility is expanding fast — choppy price action, so buckle up
- Strong cash runway (9 quarters)
- Low P/S ratio (2.4x)
- Strong revenue growth (+4069%)
- Near 52-week low (11% of range)
- Micro-cap ($5-20M) - high risk
- Sentiment is mixed — no strong consensus either way
- Revenue growing at +4069% — the top line is moving in the right direction
- Altman Z-Score grey zone (2.09, low-confidence approx)
- Penny stock risk ($0.013)
- RBA hiking (-3pts)
- Trial readout: PHASE3 (est. 2026-05-01)
Risk Signals
- Below the 200-day average — the long-term trend is still working against it
- Deeply negative margins (-54%)
- Not enough chatter to gauge sentiment — defaulting to neutral
- Long-term momentum is negative — down 38% over the past year
- The bigger volume days are the down days — volume-weighted momentum is negative (-1.42%/day)
- Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about NTI
3 free messages/day · Unlimited with Pro
Recent Catalysts
LOW Neurotech to present at NWR Virtual Healthcare Conference
NONE Corporate Presentation
NONE Results of General Meeting
NONE Appendix 4D & Half Year Report
HIGH NTI initiates First Clinical Site for Phase 3 ASD Trial
Recent ASX Announcements
| 2026-03-22 | Neurotech to present at NWR Virtual Healthcare Conference |
| 2026-03-17 | Corporate Presentation |
| 2026-03-16 | NTI initiates First Clinical Site for Phase 3 ASD Trial PRICE SENSITIVE |
| 2026-03-12 | Results of General Meeting |
| 2026-02-26 | Appendix 4D & Half Year Report PRICE SENSITIVE |
Key Metrics
$16.9M
Market Cap
919K
Avg Volume
1.6x
Vol Ratio
$0.01 — $0.04
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-66.3%
ROE
-54.4%
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 76% |
| L | Leader vs Laggard | laggard | RS: -2 |
| I | Institutional Sponsorship | weak | Inst: 3% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
Ranked #34 of 117 · Sector avg: 46
View all Healthcare signals →Track NTI and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.
No credit card required